Topics / Body Composition
Body Composition
Fat loss, muscle gain, GLP-1 drugs, protein and fasting, and what the trials actually measured.
13 guidesone evidence laddernot yet clinically reviewed
Lifestyle
2- Protein intakeNutritionHow much protein to eat, as opposed to which powder. More protein adds small muscle and strength gains with resistance training, with a threshold near 1.6 g per kg a day in younger adults. Cohorts link animal protein to slightly higher mortality, plant protein to lower.Established
- Intermittent fastingNutritionEating within a window or fasting on set days. It produces weight loss, and in head-to-head trials about the same as simply eating less. Alternate-day fasting edges ahead by about a kilogram in a 2025 network meta-analysis. The metabolic benefits beyond weight are small.Established
Supplements
1Peptides
10- SemaglutideGLP-1 receptor agonistA long-acting GLP-1 receptor agonist with large phase III programs in type 2 diabetes, obesity, and cardiovascular outcomes. One of the few entries here where the evidence base is genuinely deep.Established
- TirzepatideDual GIP and GLP-1 receptor agonistA dual incretin agonist hitting both GIP and GLP-1 receptors. Phase III results in diabetes and obesity are larger than single-agonist comparators; the mechanistic reason is still argued.Established
- TesamorelinGrowth hormone-releasing hormone (GHRH) analogA GHRH analog approved specifically for HIV-associated lipodystrophy. Frequently cited well outside that indication, on evidence that does not extend there.Established
- RetatrutideGLP-1, GIP and glucagon receptor triple agonistA triple incretin agonist with phase 2 obesity results larger than anything before it, and no completed phase 3. The most interesting unfinished story in the class.Early clinical
- LiraglutideGLP-1 receptor agonistThe daily GLP-1 agonist that came before the weekly ones. Smaller effect, longer real-world record, and a completed cardiovascular outcomes trial.Established
- Cagrilintide (AM833)Amylin receptor agonistA long-acting amylin analog, mostly studied in combination with semaglutide. A different satiety pathway to the incretins, which is the point of it.Early clinical
- Setmelanotide (RM-493)Melanocortin-4 receptor (MC4R) agonistAn MC4R agonist approved only for a handful of rare genetic obesity syndromes. A clean example of a real drug with a genuinely tiny eligible population.Established
- AOD-9604Growth hormone C-terminal fragmentA growth hormone fragment that completed a phase 2b obesity trial and did not beat placebo. One of the few entries here with a proper negative result.Early clinical
- SurvodutideDual glucagon and GLP-1 receptor agonistA dual glucagon/GLP-1 agonist in phase 3 for obesity and for MASH. Real trials, real sponsor, no approval anywhere yet, and the phase 3 readouts that matter are not published.Early clinical
- MazdutideDual glucagon and GLP-1 receptor agonist (oxyntomodulin analog)An oxyntomodulin analog developed primarily in China, further along the regulatory path there than anywhere else. Its approval status is the thing people most often get wrong about it.Early clinical
Community
Talk it through in the Body Composition room.
The guides say what the studies found. The room is where people compare what happened to them, and every post is labeled as anecdote or cited research so the two are never confused. Reading and posting take a free account.
For Research & Educational Discussion Only. Not Medical Advice
Everything on Baseline is community discussion and educational material. It is not medical care, diagnosis, treatment, or prescribing, and no one here is acting as your clinician. Talk to a licensed healthcare professional before making any decision about your health.